The natural history of neonatal group B Streptococcus (GBS) is poorly understood. Little is known about the bacterial factors influencing the transmission of GBS from mother to neonate, or the development of invasive early-onset GBS disease (EOGBS) in colonized neonates. We reviewed whether bacterial load and molecular markers are associated with GBS vertical transmission and progression to EOGBS. Methods: We searched Medline, Embase, Cochrane and Web of Science from inception to October 10, 2016, for observational studies in English. We also hand-searched reference lists of relevant publications and experts crosschecked included studies. Two reviewers independently screened studies, extracted data and appraised the quality of included studies using the Quality in Prognosis Studies tool. We conducted random-effects meta-analyses where possible and narratively synthesized the evidence in text and tables. Results: Seventeen studies were included from 1107 records retrieved from electronic databases and publication references. Meta-analyses of 3 studies showed that neonates colonized by serotype III had a higher risk of developing EOGBS than serotype Ia (pooled risk ratio: 1.51, 95% confidence interval: 1.12-2.03) and serotype II (risk ratio: 1.95, 95% confidence interval: 1.10-3.45). Eleven studies showed that in heavily colonized mothers, 2-3 times more neonates were colonized, and in heavily colonized neonates, up to 15 times more neonates had EOGBS, compared with light colonization. Most evidence was published before 2000 and was at risk of bias. Conclusions: Acknowledging the difficulty of natural history studies, wellcontrolled studies are needed to assess the predictive value of pathogen subtype and heavy load; they may be useful for better-targeted prevention.
G roup B Streptococcus (GBS) is a leading cause of morbidity and mortality from neonatal sepsis. 1 Early-onset GBS disease (EOGBS, first 6 days of life) has a global estimated incidence of 0.4 per 1000 live births and a case fatality rate of 12.1%, although this incidence is likely to be an underestimate. 2 A precondition for EOGBS is maternal GBS colonization of the gastrointestinal and/ or genitourinary tract. A meta-analysis found that GBS colonizes approximately 17.9% of women globally, from 11.1% in Southeast Asia to 22 .4% in Americas. 3 If a woman has GBS vaginal colonization during labor, there is approximately a 36% chance that GBS might be transmitted to her neonate. 4 Without treatment, most neonates colonized with GBS will be asymptomatic, but a small proportion (around 1%) will have EOGBS. 5 The natural history of GBS disease is poorly understood. There is a paucity of data on the pathogen-specific factors influencing the transmission of GBS colonization from mother to neonate or the development of invasive EOGBS in colonized neonates. Of 10 GBS polysaccharide capsule types, serotype Ia, Ib, II, III and V are more commonly responsible for EOGBS. [5] [6] [7] A number of virulence factors, such as clonal complexes and surface proteins, have also been proposed in laboratory and clinico-epidemiologic studies, [8] [9] [10] and maternal bacterial load has been associated with increased neonatal colonization and sepsis. 11 Data on the GBS characteristics that increase the risk of neonatal colonization and EOGBS may have important implications for targeting intrapartum antibiotic prophylaxis (IAP) prevention to only those women at most risk of having a baby with EOGBS. This may reduce exposure to the potential harms associated with IAP, such as antimicrobial resistance and Gram-negative infections as a result of selection pressure and mutations of the organisms causing infection.
12,13 Therefore, we systematically reviewed the evidence on the bacterial load and bacterial molecular markers associated with GBS vertical transmission, and progression from neonatal GBS colonization to EOGBS.
MATERIALS AND METHODS
This systematic review is reported according to recommendations from the Preferred Reporting Items for Systematic Review and Meta-analysis Protocols 2015 statement. 14 The protocol is registered at the International Prospective Register of Systematic Reviews: CRD42016037196.
Search Strategy and Selection Criteria
We conducted electronic searches in MEDLINE, MEDLINE In-Process and Other Non-Indexed Citations, EMBASE, Cochrane Library: Cochrane Database of Systematic Reviews, CENTRAL, DARE and HTA databases and Science Citation Index Expanded from inception to October 10, 2016 . The search combined both text words and MeSH terms for GBS, neonate/pregnancy and bacterial load/molecular markers and was limited to English and humans (Supplemental Digital Content, http://links.lww.com/INF/D106). We hand-searched reference lists of included studies and relevant systematic reviews and experts cross-checked included studies.
Two reviewers independently screened titles, abstracts and full texts of all identified records. Any disagreements were resolved by discussion, with involvement of a third reviewer if necessary. We included cohort or case-control studies that evaluated the association between bacterial load or any individual molecular marker with the transition of GBS from (1) maternal colonization in the third trimester to neonatal colonization or EOGBS (as defined by authors, ideally confirmed by culture from a sterile site; fewer than 7 days), (2) maternal colonization in labor to neonatal colonization or EOGBS or (3) neonatal colonization to EOGBS. We excluded studies in which more than 10% participants were pregnant women before the third trimester [for study objective (1) above] or neonates who had late-onset GBS. However, we included any studies where the data for mothers in the third trimester or for neonates less than 7 days of age could be separated from the other participants regardless of the percentage of total participants that met the exclusion criteria. We also excluded studies in which participants received an intervention that would interfere with GBS transmission, such as IAP treatment or elective caesarean section delivery as well as any studies that were conducted in the context of IAP treatments. Finally, we excluded case reports, case series, abstracts, reviews, editorials, letters, books, consensus statements and opinions.
Data Extraction and Quality Assessment
Two reviewers independently extracted relevant data on an a priori defined and piloted extraction sheet. Data included study settings, participants, bacterial factors, outcomes and results. Two authors independently appraised the risk of bias of included studies using the Quality in Prognosis Studies tool, judging 6 risk of bias domains as low, moderate or high. 15 Any disagreements were resolved by discussion, with involvement of a third reviewer if necessary.
Data Synthesis
All analyses were conducted in Stata 14 (Stata Corp, College Station, TX). Where data permitted, we calculated odds ratios for case-control studies and risk ratios (RRs) for all other designs, along with 95% confidence intervals (CIs). We only conducted meta-analyses on the serotypes associated with progression from neonatal GBS colonisation to EOGBS because of heterogeneity in the studies on the remaining factors. We used a random effects model because of anticipated between-study differences. 16 As only raw numbers and proportions were reported in the studies and summary measures such as RRs were not, we calculated the RRs and 95% CIs for each study and pooled them using STATA command metan. Heterogeneity was assessed using forest plots, the χ 2 test for heterogeneity with a 10% level of statistical significance and the I 2 statistic where a value of less than 50% represents low to moderate heterogeneity. 17 Comparisons were only made for serotypes included in at least 2 studies. For the remaining studies, we conducted narrative syntheses and displayed results in tables and text.
RESULTS
Our search identified 1107 unique records, of which 17 articles were included in the synthesis (see Fig. 1 and 1 investigated C-protein antigen.
21
Risk of Bias Figure 2 shows the methodologic quality of included studies. Risk of bias was considered high in 2 or more Quality in Prognosis Studies domains in 10 of 17 studies (59%), and in 1 domain in 4 of 17 studies (24%). No study was judged as low risk of bias in all 6 domains. The study confounding domain had the highest risk of bias, as important potential confounders such as gestational age at birth, birth weight, intrapartum fever and prolonged rupture of membranes were not accounted for in 76% of study designs (13/17, high risk). 7, 18, [20] [21] [22] [23] [24] [25] [26] 28, 29, 32, 33 The remaining 4 accounted for some, but not all, relevant confounders (moderate risk). 19, 27, 30, 31 In the study participation domain, 9 studies (53%) [18] [19] [20] [21] [22] [23] 25, 26, 33 were at high risk and the remaining 8 were at moderate risk of selection bias 7, 24, [27] [28] [29] [30] [31] [32] as baseline characteristics were not adequately described and/or recruitment methods were not fully stated.
Serotypes
Information on serotypes associated with GBS transmission from mother to neonate was available from 1 study. Al-Sweih et al 18 found that mothers colonized with serotypes V (13/27, 48%) and Ia (5/11, 45%) on vaginal-anorectal swabs were more likely to transmit GBS than mothers colonized with Ib (1/3, 33%), III (11/33, 33%), serotypes not typeable (7/22, 32%) and the remaining serotypes.
Information on serotypes associated with progression from GBS neonatal colonization to EOGBS was available in 5 studies. 7, 19, 21, 31, 32 Meta-analyses could only be performed on 3 studies, 7, 21, 32 as the required data were not available in the others. Of the omitted studies, Baker and Barrett 19 reported that serotype III was more frequently present in EOGBS cases (56%) than in asymptomatic colonisation (36%). However, in this study, the number of participants in the asymptomatic GBS colonization group was inconsistently reported; therefore, the number of participants with each serotype could not be calculated. Similarly, Baker and Barrett 31 inconsistently reported the number of individuals with GBS sepsis, so the numbers could not be calculated from this study either.
The pooled RRs from the meta-analyses for EOGBS in neonates colonized by comparisons of GBS serotypes are shown in Figure 3 . 
Bacterial Load
Eleven studies investigated bacterial load, and although they defined load differently, studies agreed that heavy maternal load was more strongly associated with GBS transmission, and heavy neonatal load more strongly associated with EOGBS, compared with light load (Table 2) . 20, [22] [23] [24] [25] [26] [27] [28] [29] [30] 33 Three studies reported the number of colonized sites. 22, 25, 33 Hoogkamp-Korstanje et al 25 found that women colonized in 2 or more sites compared with 1 site only were two and a half times more likely to have a neonate colonized with GBS (91% vs. 36%, RR calculated from percentages: 2.53, 95% CI: 1.93-3.31). Sites swabbed included throat, nose, vagina, cervix, rectum and midstream urine in labor. Similarly, 2 studies found up to a 15 times higher risk of EOGBS in neonates with 3 to 4 colonized sites compared with 1 to 2 colonized sites (see Table 2 for results). 22, 33 Sites reported in these studies were external ear canal, umbilicus, oropharynx and rectum within an hour of birth, 22 and external canal, umbilicus, throat and anus within 1-2 hours of birth. 33 Three studies reported the number of colony counts on a plate. [23] [24] [25] Hoogkamp-Korstanje et al 25 found that heavy maternal colonization (>50 colonies, 87% transmission rate) in labor was associated with GBS transmission more often than light (<10 colonies, 30% transmission rate) or moderate colonization (10-50 colonies, 50% transmission rate). Gerards et al 24 combined the number of sites with the number of colony counts, finding that neonates colonized in 3 or more sites with >50 colonies (heavy, 4/8, 50% transmission rate) were more likely to have EOGBS than neonates with fewer than 3 sites with >50 colonies, 3 or more sites with <10 or 10-50 colonies (moderate, 15/35, 42.9% transmission rate) or fewer than 3 sites with <10 or 10-50 colonies (light, 2/44, 4.5% transmission rate). Sites swabbed were nose, throat, external auditory meatus, eyes, umbilicus, skin and rectum immediately after admission to neonatal intensive care unit. Easmon et al 23 also reported the number of colonies in mothers' vaginas and rectum; however, conclusions could not be drawn as data labeling in their report was unclear.
Three studies investigated colony-forming units (CFU) of GBS finding that the risk of vertical GBS transmission and EOGBS increases with CFU of GBS. 26, 29, 30 Jones et al 26 found a statistically significant linear correlation (P < 0.001) between the CFU of GBS in mothers' vaginas during delivery and neonates' rectums at birth, but a poor correlation between CFU of GBS in infant umbilical or nasopharyngeal culture with that found in the mother's vagina. They also found that mothers' swabs had to contain at least 10 2 GBS before their neonate's swab yielded a positive result, and that neonates colonized with ≥10 5 GBS per rectal swab were delivered by mothers colonized with ≥3 × 10 4 GBS per vaginal swab. Three infants developed EOGBS; 2 had blood culture positive sepsis and 1 had a positive rectal culture with respiratory distress. All 3 infants had mothers who 
C-protein Antigen
Chun et al 21 examined whether asymptomatic GBS and EOGBS strains reacted to C-protein antiserum and 4 antigens-α, β, γ, δ. They found that GBS isolates in 87% (41/47) of neonates with EOGBS and 73% (54/74) of asymptomatically colonized individuals reacted to C-protein antiserum; this difference was not statistically significant. When comparing the distribution of the 4 C protein-associated antigens, antigen δ was expressed more often in isolates from neonates with EOGBS (12/41, 29%) than in asymptomatic neonates (10/54, 19%). The remaining antigens were present less often in EOGBS (α = 28/41, 68%, β = 7/41, 17% and γ = 15/41, 36.5%) than in healthy neonates (α = 44/54, 81%, β = 15/54, 28% and γ = 20/54, 37%). Summary measures were not calculated as more than 1 antigen can be expressed in 1 strain. 
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DISCUSSION
This is the first systematic review investigating bacterial load and molecular markers associated with GBS vertical transmission, or progression from neonatal colonization to EOGBS. Our findings suggest that the epidemiology and natural history of neonatal GBS have not been extensively researched. Only 2 bacterial markers have been investigated in addition to bacterial load, and most of the evidence is published before 2000 and at high risk of bias. While IAP can reduce EOGBS morbidity, 34 there are potential harms associated with it, 35 and in current prevention approaches some mothers and their neonates may be unnecessarily treated and exposed to these potential harms. For example, in a screening program, up to 30% of GBS positive pregnant women may become negative by birth, 36 and only 1% of GBS positive women in labor will have a baby with EOGBS; 5 all of these women and their neonates would be unnecessarily treated and potentially exposed to the harms. Similarly, approximately 5% of GBS negative pregnant women may become positive by birth and would not be treated. Bacterial factors could provide innovative opportunities for more efficient prevention, allowing patients with the hypervirulent strains of GBS to be targeted, avoiding unnecessary exposure to IAP and reducing potential undertreatment. Bacterial load is the most promising of the factors, as irrespective of how it was defined and measured, heavier load was consistently associated with GBS transmission and EOGBS. Women colonized with heavy GBS load had approximately 2-3 times higher risk of having a neonate colonized with GBS compared with mothers with light load. Heavier GBS load in neonates was also consistently associated with EOGBS. The pooled comparison of serotypes in GBS colonized neonates showed that the risk of EOGBS disease was highest for neonates colonized with serotype III.
Previous literature shows that serotype III, along with Ia, Ib, II and V, is one of the most frequently identified invasive neonatal serotypes.
2,5-7 Our review showed that compared with Ia and , for example, found no cases of EOGBS in neonates with a nontypeable serotype compared with 8% of colonized mothers who had a nontypeable serotype. We may not have found this difference in our review as there were only 23 neonates colonized with a nontypeable serotype in the meta-analysis. Within serotype III, a study excluded from this review because of the context of IAP, found that ST-17 was the most common sequence type among invasive serotype III strains. 10 Laboratory experiments have demonstrated that a determinant of this hypervirulence is a ST-17-specific surface protein, which promotes attachment to intestinal and meningeal cells. 38 ST-17 is also more likely to invade decidual cells than colonizing strains. 39 The finding that heavy bacterial load is consistently associated with GBS vertical transmission and EOGBS is in line with evidence that women with GBS bacteriuria (a surrogate for heavy maternal colonization) have a higher risk of delivering neonates who develop EOGBS. 40, 41 There is also more recent evidence (excluded as the study was conducted in the context of IAP) showing that heavy neonatal colonization as defined by the number of sites is more strongly associated with EOGBS than light load (25/1000 vs. 4/1000, respectively, P < 0.001). 42 In contrast, evidence on the association directly between maternal load and EOGBS was slightly unclear, possibly because of the small numbers of EOGBS in such studies. We were only able to perform analyses on 1 study, where preterm EOGBS was almost 4 times more likely in infants with heavily colonized mothers. 27 Several limitations of the evidence should be considered. The risk of bias across the evidence was high or moderate, especially regarding confounding variables and study participation domains. Furthermore, we calculated the point and interval estimates (RRs, odds ratios and 95% CIs) reported in this review using unadjusted statistical analyses that did not control for potential confounders. Therefore, the identified relationships could be partially or entirely because of confounding factors. Majority of the evidence is also published before 2000 and may not be applicable to today's context. For example, the association of serotypes with invasive disease may be influenced by circulating strains or clones rather than serotype alone, and these associations may change over time. To fully understand the mechanisms of virulent GBS types, and to confirm that bacterial load is independently associated with EOGBS, larger and better-controlled studies are required. We acknowledge that such a study may no longer be feasible as IAP is now the recommended treatment. However, it may be possible to conduct a prospective cohort study in contexts where IAP prevention is not adopted, for example, in countries in Africa or Asia. Alternatively, it might be possible to conduct a retrospective cohort study on culture positive mothers who did not end up being treated in screening programs across countries. Clinical studies are required to confirm findings on other virulence factors indicated from laboratory studies, 8, 9 as they are not yet available.
There are also some limitations of our review. Studies in which participants were given IAP were excluded, as IAP would interfere with the natural history of GBS transmission and progression to EOGBS. This may have resulted in the exclusion of more recent studies, as it may be less feasible to conduct studies on untreated women only. As such, it may be worth systematically reviewing whether serotype, bacterial load and other factors predict risk of transmission and EOGBS in the presence of IAP. As non-English studies were also excluded, prognostic studies in other languages may have been missed.
CONCLUSIONS
While IAP treatment can reduce EOGBS morbidity, 34 the persistence of EOGBS combined with the potential harms from IAP stress the need for better targeted prevention and therapy. Bacterial load, serotype, sequence type and the more specific isolate characterization feasible with the advent of genome sequencing could potentially be involved in guiding future prevention interventions. There is good evidence to further investigate serotype, and particularly bacterial load, in better quality studies. Beyond these factors, greater insights into the mechanisms which underlie the natural history of GBS vertical transmission and EOGBS are essential for the development of new interventions to prevent EOGBS. 
